Research programme: cholesterol transport modulators - Gilead Sciences

Drug Profile

Research programme: cholesterol transport modulators - Gilead Sciences

Alternative Names: CVT-10176; CVT-11130

Latest Information Update: 15 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CV Therapeutics
  • Developer Gilead Sciences
  • Class
  • Mechanism of Action Apolipoprotein A I stimulants; ATP binding cassette transporter 1 stimulants; Liver X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Tangier disease

Most Recent Events

  • 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences
  • 15 Jun 2007 This programme is still in active development
  • 06 Jan 2000 Preclinical development for Atherosclerosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top